We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Mawi DNA

Mawi DNA Technologies develops unique biosample collection technologies enabling universal sample collection from any... read more Featured Products: More products

Download Mobile App





Swab with Unique Head Design Enables Accurate, More Reliable COVID-19 Test Results

By LabMedica International staff writers
Posted on 11 May 2022
Print article
Image: NextSWAB enables accurate, more reliable COVID-19 test results (Photo courtesy of Mawi DNA)
Image: NextSWAB enables accurate, more reliable COVID-19 test results (Photo courtesy of Mawi DNA)

Current sample collection methods for COVID-19 testing commonly face problems of low recovery, high bacterial content, low quality DNA, and excessive resampling costs. Now, a newly-launched 100% medical-grade plastic swab is designed for high efficiency collection without the possibility of contamination from glue or fibers used in flock and cotton swabs that may inhibit PCR based assays.

In response to the COVID-19 swab shortage, Mawi DNA Technologies (Hayward, CA, USA) has launched the NextSWAB that is currently optimized for nasal sample collection with validation for other sample types ongoing. The NextSWAB is compatible with many sample transport tubes making it ideal for multiple swab sample pooling in a single tube. However, to achieve optimal results, it is most effective when used in conjunction with Mawi’s iSWAB-Microbiome-EL sample collection technology which allows users to skip the RNA extraction step in COVID-19 molecular tests. A second nasal sample can be added to the same tube creating a more concentrated sample to improve overall reliability of the test. The NextSWAB comes ready for use and does not require any preparation for specimen collection.

“The NextSWAB sterile sampling applicator is six inches in length with a unique head design positioned at the distal end,” said Dr. Bassam El-Fahmawi, CEO of Mawi. “The swab head has two channels separated by a septum that retains the collected nasal material which can then be released into the transport media with a gentle shake. The flexible head fits into crevices with ease and effectiveness. It enables anterior nasal sample collection with minimal user discomfort sufficient for a meaningful result.”

“Our NextSWAB fully releases its contents into the sample transport media removing the need for the swab to be transported with the sample,” added Dr. El-Fahmawi. “A fully concentrated liquid sample can then be quickly processed with robotic liquid handling systems or any laboratory workflow. During initial R&D testing, the unique and patent pending head design has shown higher collection efficiency for nasal (mid-turbinate and anterior nares) samples than flocked swabs.”

Related Links:
Mawi DNA Technologies 

Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.